Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Kellie Turner"'
Autor:
Jill C. Chappell, Alan Y. Chiang, Jane Royalty, Hugh Coleman, Palaniappan Kulanthaivel, P. Kellie Turner
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 9, Pp 1617-1627 (2023)
Abstract Abemaciclib is an orally administered, potent, and selective small molecule inhibitor of cyclin‐dependent kinases 4 and 6, approved for advanced or metastatic breast cancer. This study aimed to use an exposure–response approach to invest
Externí odkaz:
https://doaj.org/article/7d79069f08db4c7885afaca6440b2721
Autor:
Emmanuel Chigutsa, Siva Rama Prasad Kambhampati, Amanda Karen Sykes, Maria M. Posada, Jan‐Stefan van derWalt, P. Kellie Turner
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 9, Pp 523-533 (2020)
Abemaciclib is an oral anticancer drug that inhibits cyclin dependent kinases 4 and 6 and is metabolized by cytochrome P450 3A in the intestines and liver to active metabolites. The objectives were (1) to develop a mechanistic model to characterize t
Externí odkaz:
https://doaj.org/article/aae48a8a620d4e158d398b92e2b3e234
Autor:
Jonathan W. Goldman, Julien Mazieres, Fabrice Barlesi, Konstantin H. Dragnev, Marianna Koczywas, Tuncay Göskel, Alexis B. Cortot, Nicolas Girard, Claas Wesseler, Helge Bischoff, Ernest Nadal, Keunchil Park, Shun Lu, Alvaro Taus, Manuel Cobo, Shawn T. Estrem, Sameera R. Wijayawardana, Kellie Turner, Gerard Joseph Oakley, Karla C. Hurt, Alan Y. Chiang, Anwar M. Hossain, William J. John, Luis Paz-Ares
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
IntroductionJUNIPER compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, with erlotinib in patients with non-small cell lung cancer (NSCLC) harboring a Kirsten rat sarcoma (KRAS) mutation.MethodsJUNI
Externí odkaz:
https://doaj.org/article/4c938db73a4443b18e2317f0a0f304fd
Autor:
Franck Morschhauser, Kamal Bouabdallah, Stephan Stilgenbauer, Catherine Thieblemont, Sophie de Guibert, Florian Zettl, Lawrence M. Gelbert, P. Kellie Turner, Siva Rama Prasad Kambhampati, Li Li, Lily Q. Li, Sean Buchanan, Susana Barriga, Melissa M. Bear, Martin Wilhelm, Georg Hess
Publikováno v:
Haematologica, Vol 106, Iss 3 (2020)
Externí odkaz:
https://doaj.org/article/d1330710d90f43f6a096ac0bba1735f1
Autor:
Jonathan W. Goldman, William J. John, Anwar Hossain, Richard Beckmann, Siva Rama Prasad Kambhampati, P. Kellie Turner, Erica L. Johnston, Monte Shaheen, Eric Schaefer, Mariano Provencio, Martin Gutierrez, Daruka Mahadevan, Shadia Jalal, Pilar Garrido, Luis G. Paz-Ares, Karen Kelly, Edward S. Kim
Third part of the appendix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::242623715c2e35989bbd2a74c402090e
https://doi.org/10.1158/1078-0432.22470783.v1
https://doi.org/10.1158/1078-0432.22470783.v1
Autor:
Jonathan W. Goldman, William J. John, Anwar Hossain, Richard Beckmann, Siva Rama Prasad Kambhampati, P. Kellie Turner, Erica L. Johnston, Monte Shaheen, Eric Schaefer, Mariano Provencio, Martin Gutierrez, Daruka Mahadevan, Shadia Jalal, Pilar Garrido, Luis G. Paz-Ares, Karen Kelly, Edward S. Kim
Purpose: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated preclinical activity in non–small cell lung cancer (NSCLC). A multicenter, nonrandomized, open-label phase Ib study was conducted to test safety, MTD, phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::247771de316daddf898dbc0b82a5449e
https://doi.org/10.1158/1078-0432.c.6527679
https://doi.org/10.1158/1078-0432.c.6527679
Autor:
Michaela Banck, James E. Wooldridge, Volker Wacheck, Jay Tuttle, Xuejing Aimee Wang, Tianle Hu, Brian Moser, P. Kellie Turner, Alain P. Algazi, Jonathan W. Goldman, Lee S. Rosen
Table S1. Treatment emergent adverse events regardless of causality in {greater than or equal to}10% of patients; Table S2. Best Overall Response; Table S3. Reasons for Emibetuzumab Discontinuation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f81cf969170c12c35f49188178d97ea
https://doi.org/10.1158/1078-0432.22466984
https://doi.org/10.1158/1078-0432.22466984
Autor:
Jonathan W. Goldman, William J. John, Anwar Hossain, Richard Beckmann, Siva Rama Prasad Kambhampati, P. Kellie Turner, Erica L. Johnston, Monte Shaheen, Eric Schaefer, Mariano Provencio, Martin Gutierrez, Daruka Mahadevan, Shadia Jalal, Pilar Garrido, Luis G. Paz-Ares, Karen Kelly, Edward S. Kim
First part of the appendix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43cd31f5d7f6762afe34223c2a1cdecd
https://doi.org/10.1158/1078-0432.22470777
https://doi.org/10.1158/1078-0432.22470777
Autor:
Michaela Banck, James E. Wooldridge, Volker Wacheck, Jay Tuttle, Xuejing Aimee Wang, Tianle Hu, Brian Moser, P. Kellie Turner, Alain P. Algazi, Jonathan W. Goldman, Lee S. Rosen
Treatment duration by patient and emibetuzumab dose for emibetuzumab monotherapy (A) and emibetuzumab + erlotinib (B).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69fb06598929ea674cc0d01332209f77
https://doi.org/10.1158/1078-0432.22466990
https://doi.org/10.1158/1078-0432.22466990
Autor:
Michaela Banck, James E. Wooldridge, Volker Wacheck, Jay Tuttle, Xuejing Aimee Wang, Tianle Hu, Brian Moser, P. Kellie Turner, Alain P. Algazi, Jonathan W. Goldman, Lee S. Rosen
Purpose: The MET/HGF pathway regulates cell proliferation and survival and is dysregulated in multiple tumors. Emibetuzumab (LY2875358) is a bivalent antibody that inhibits HGF-dependent and HGF-independent MET signaling. Here, we report dose escalat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::004e241de2f3f7f6a81fbcc39945ee89
https://doi.org/10.1158/1078-0432.c.6526499
https://doi.org/10.1158/1078-0432.c.6526499